Featured Research

from universities, journals, and other organizations

New Treatment Options For Children With ADHD

Date:
February 26, 2002
Source:
University Of Rochester Medical Center
Summary:
Neurologists have shown that many children with attention deficit hyperactivity disorder (ADHD) who have long been denied the medication most commonly used by doctors, methylphenidate (MPH, also known as Ritalin), can be treated effectively with it. The study in the February 26 issue of Neurology, published by the American Academy of Neurology, also puts forth the idea that a combination of medicines works best for many children with ADHD.

Neurologists have shown that many children with attention deficit hyperactivity disorder (ADHD) who have long been denied the medication most commonly used by doctors, methylphenidate (MPH, also known as Ritalin), can be treated effectively with it. The study in the February 26 issue of Neurology, published by the American Academy of Neurology, also puts forth the idea that a combination of medicines works best for many children with ADHD.

Related Articles


“This is an effective medicine that doctors have been told for decades not to use in children with tics, such as children with Tourette’s syndrome,” says lead author Roger Kurlan, M.D., a neurologist at the University of Rochester Medical Center. “There’s even a warning in the Physician’s Desk Reference, and for 40 years physicians have avoided treating children with ADHD and tics with Ritalin because of a fear that the tics would worsen. But the warning was based on slim evidence and had never really been checked out thoroughly.”

The study was conducted by the Tourette’s Syndrome Study Group, a collection of physicians and nurses from 15 institutions who focus on developing and testing new treatments for the disorder. About one-third of children diagnosed with ADHD also have a tic disorder like Tourette’s.

Since about half of children with tics also have ADHD, doctors like Kurlan who specialize in treating children with Tourette’s long encountered difficulty treating many of their patients. Many specialists had found MPH effective at treating children with tics and ADHD, despite the conventional thinking. So the Tourette’s study group proposed to settle the question in a study which the National Institutes of Health agreed to fund.

Doctors at 12 hospitals and medical centers around North America studied 136 children ages 7-14 who had both ADHD and tics. Children received either MPH, clonidine, both, or neither; doctors, nurses, parents, teachers and children did not know which children received which treatment until the study was completed. Children were examined by nurses and doctors, and their behavior was monitored and reported by parents and teachers for 16 weeks.

Kurlan says doctors had assumed MPH shouldn’t be used in children with Tourette’s because it was thought that the medicine, a stimulant, would worsen tics. But the study found otherwise: Not only did youngsters treated with MPH experience no more tics than their counterparts not on MPH, dispelling that long-held notion, but the medicine actually eased their tics. The same was true for children in the other two groups that received medication.

“This longstanding practice has left a large number of children in a difficult situation,” Kurlan says. “Though they have ADHD, their doctors have been told not to give these children the best available treatment. It’s been frustrating for doctors, and there are many parents out there who have felt cheated out of an effective treatment for their children with ADHD.”

The study marks the first time that MPH has been tested in children with tics; it’s also the first time that the effectiveness of ADHD and clonidine have been tested head to head in any children with ADHD.

The findings may spur changes in treatment for all children with ADHD, not just those with tics, the investigators say. The group also compared the effects of the combination of MPH and clonidine to MPH alone and clonidine alone. Doctors found that the combination was more effective than either medication alone. The drugs seem to complement each other, with MPH more effective helping children concentrate and clonidine helping counter patients’ impulsivity and hyperactivity.

“This makes possible the whole idea of individualizing medication treatment,” Kurlan says. “It makes sense for a doctor to think of the individual patient and which symptom is most bothersome to that patient. If hyperactivity is dominant, the doctor might prescribe clonidine; if the child is have trouble focusing, methylphenidate makes sense.”


Story Source:

The above story is based on materials provided by University Of Rochester Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

University Of Rochester Medical Center. "New Treatment Options For Children With ADHD." ScienceDaily. ScienceDaily, 26 February 2002. <www.sciencedaily.com/releases/2002/02/020226075048.htm>.
University Of Rochester Medical Center. (2002, February 26). New Treatment Options For Children With ADHD. ScienceDaily. Retrieved March 31, 2015 from www.sciencedaily.com/releases/2002/02/020226075048.htm
University Of Rochester Medical Center. "New Treatment Options For Children With ADHD." ScienceDaily. www.sciencedaily.com/releases/2002/02/020226075048.htm (accessed March 31, 2015).

Share This


More From ScienceDaily



More Health & Medicine News

Tuesday, March 31, 2015

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Soda, Salt and Sugar: The Next Generation of Taxes

Soda, Salt and Sugar: The Next Generation of Taxes

Washington Post (Mar. 30, 2015) — Denisa Livingston, a health advocate for the Dinι Community Advocacy Alliance, and the Post&apos;s Abby Phillip discuss efforts around the country to make unhealthy food choices hurt your wallet as much as your waistline. Video provided by Washington Post
Powered by NewsLook.com
UnitedHealth Buys Catamaran

UnitedHealth Buys Catamaran

Reuters - Business Video Online (Mar. 30, 2015) — The $12.8 billion merger will combine the U.S.&apos; third and fourth largest pharmacy benefit managers. Analysts say smaller PBMs could also merge. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
S. Leone in New Anti-Ebola Lockdown

S. Leone in New Anti-Ebola Lockdown

AFP (Mar. 28, 2015) — Sierra Leone imposed a three-day nationwide lockdown Friday for the second time in six months in a bid to prevent a resurgence of the deadly Ebola virus. Duration: 01:17 Video provided by AFP
Powered by NewsLook.com
These Popular Antibiotics Can Cause Permanent Nerve Damage

These Popular Antibiotics Can Cause Permanent Nerve Damage

Newsy (Mar. 27, 2015) — A popular class of antibiotic can leave patients in severe pain and even result in permanent nerve damage. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins